Plumbagin enhances TRAIL-mediated apoptosis through up-regulation of death receptor in human melanoma A375 cells

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anti-cancer agent. However, emergence of drug resistance limits its potential use. Plumbagin is a natural quinonoid compound isolated from plant. In this study, induced apoptosis effect of the combined treatment with plumbagin and TRAIL on human melanoma A375 cell line was examined and possible mechanism was investigated. The cells were divided into four groups: control group, plumbagin group (plumbagin, 5 or 10 μmol/L), TRAIL group (TRAIL, 30 ng/mL) and plumbagin+TRAIL group (combined treatment group). The apoptosis, and the expression of DR4 and DR5 were detected by flow cytometry. The activities of caspase-8 and caspase-3 were determined by colorimetric assay. The results showed that the apoptosis rate was 8.3% in TRAIL group, 10.35%-16.94% in plumbagin group and 52.39%–65.39% in combined treatment group, respectively, with the difference being significant between combined treatment group and plumbagin or TRAIL group (P<0.05 for each). Moreover, plumbagin alone could markedly up-regulate DR5 mRNA and protein expression, and slightly increase DR4 mRNA and protein expression. Treatment of human melanoma A375 cells with plumbagin resulted in the activation of Caspase-3, but not Caspase-8. These results suggest that plumbagin might be useful for TRAIL-based treatment for melanoma.

Keywords

plumbagin / TRAIL / DR5 / DR4 / apoptosis / melanoma

References

[1] HsiehY.J., LinL.C., TsaiT.H.. Determination and identification of plumbagin from the roots of Plumbago zeylanica L. by liquid chromatography with tandem mass spectrometry. Chromatogr A, 2005, 1083(1–2): 141-145

[2] MossaJ.S., El-FeralyF.S., MuhammadI.. Antimycobacterial constituents from Juniperus procera, Ferula communis and Plumbago zeylanica and their in vitro synergistic activity with isonicotinic acid hydrazide. Phytother Res, 2004, 18(11): 934-937

[3] SrinivasP., GopinathG., BanerjiA., et al.. Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol Carcinog, 2004, 40(4): 201-211

[4] DingY., ChenZ.J., LiuS., et al.. Inhibition of Nox-4 activity by plumbagin, a plant-derived bioactive naphthoquinone. Pharm Pharmacol, 2005, 57(1): 111-116

[5] HsuY.L., ChoC.Y., KuoP.L., et al.. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. Pharmacol Exp Ther, 2006, 318(2): 484-894

[6] KuoP.L., HsuY.L., ChoC.Y., et al.. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther, 2006, 5(12): 3209-3221

[7] PowolnyA.A., SinqhS.V.. Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm Res, 2008, 25(9): 2171-2180

[8] SandurS.K., IchikawaH., SethiG., et al.. Plumbagin (5-hydroxy-2-methyl-1,4-aphthoquinone) suppresses NF-kappaB activation and NF-kappaBregulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. Biol Chem, 2006, 281(25): 17 023-17033

[9] KawiakA., PiosikJ., StasilojcG., et al.. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol Appl Pharmacol, 2007, 223(3): 267-276

[10] NagataS.. Apoptosis by death factor. Cell, 1997, 88(3): 55-65

[11] AshkenaziA., DixitV.M.. Death receptors: signling and modulation. Science, 1998, 281(5381): 1305-1308

[12] WalczakH., KrammerP.H.. The CD95(APO-1/Fas) and the TRAIL(APO-2L) apoptosis systems. EXP CELL Res, 2000, 256(1): 58-66

[13] WalczakH., MillerR.E., AriailK., et al.. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 1999, 5(2): 157-163

[14] AshkenaziA., PaiR.C., FongS., et al.. Safety and antitumor activity of recombinant soluble Apo2 ligand. Clin Invest, 1999, 104(2): 155-162

[15] NguyenD.T., ZhangX.D., HerseyP.. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res, 2001, 7(3Supple): 966s-973s

[16] ZhangX.D., WuJ.J., GillespieS.K., et al.. Human melamoma cells selected for resistant to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnernable to non-apoptosis cell death induced by cisplatin. Clin Cancer Res, 2006, 12(4): 1355-1364

[17] WuJ.J., ZhangX.D., GillespieS., et al.. Selection for TRAIL resistance results in melanoma cells with high prolifeative potential. FEBS Lett, 2005, 579(9): 1940-1944

[18] KurbanovB.M., GeilenC.C., FeckerL.F., et al.. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Invest Dermatol, 2005, 125(5): 1010-1019

[19] KurbanovB.M., FeckerL.F., GeilenC.C., et al.. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptosis proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene, 2007, 26(23): 3364-3377

[20] ShankarS., ChenX., SrivastavaR.K.. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate, 2005, 62(2): 165-186

[21] ShankarS., SinghT.R., SrivastavaR.K.. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate, 2004, 61(1): 35-49

[22] SinghT.R., ShankarS., ChenX., et al.. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res, 2003, 63(17): 5390-5400

[23] SinghT.R., ShankarS., SrivastavaR.K.. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene, 2005, 24(29): 4609-4623

[24] ShankarS., SinghT.R., ChenX., et al.. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol, 2004, 24(5): 1133-1140

[25] ShankarS., SinghT.R., FandyT.E., et al.. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: Involvement of both death receptor and mitochondrial pathways. Int J Mol Med, 2005, 16(6): 1125-1138

[26] ZhuangL., LessC.S., ScolyerR.A., et al.. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-induced ligand. Hum Pathol, 2006, 37(10): 1286-1294

[27] Van GeelenC.M., de VriesE.G., de JongS.. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat, 2004, 7(6): 345-358